ANEB - Anebulo Pharmaceuticals, Inc.
Replimune Group (NASDAQ: REPL - Get Free Report) and Anebulo Pharmaceuticals (NASDAQ: ANEB - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Risk and Volatility Replimune Group has a
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2025, and recent updates. Second Quarter Fiscal Year 2026 and Subsequent Highlights: On February 6, 2026, Anebulo announced that the Company's board of directors (the “Board”) approved th.
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Company's board of directors (the “Board”) has approved the voluntary delisting of the Company's common stock from The Nasdaq Capital Market (“Nasdaq”) and the subsequent voluntary deregistration of its common stock with the U.S. Securi.
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB - Get Free Report)'s stock price dropped 13.6% on Thursday. The stock traded as low as $0.8031 and last traded at $0.8212. Approximately 42,620 shares were traded during trading, a decline of 31% from the average daily volume of 62,014 shares. The stock had previously closed at $0.9501. Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB - Get Free Report)'s share price was down 13.6% during trading on Thursday. The company traded as low as $0.8031 and last traded at $0.8212. Approximately 42,620 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 62,014 shares. The stock had previously closed
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the fi.
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer.